Drug Class Detail

Drug Class FLT3 Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
TAK-901 Aurkb Inhibitors 17 FGFR2 Inhibitor 15 FLT3 Inhibitor 48 TAK-901 is a selective inhibitor of Aurora B kinase, FLT3, and FGFR2, and has demonstrated anti-tumor activity in several cancer models (PMID: 23358665).
FF-10101 FF-10101-01 CSF1R Inhibitor 22 FLT3 Inhibitor 48 KIT Inhibitor 48 FF-10101 is a second generation and irreversible inhibitor of Flt3, including the internal tandem duplication (FLT3-ITD) and known resistance mutations (D835Y, Y842C, Y842H, or F691L) and also inhibits Kit and Csf1r (Fms) (PMID: 29187377)
Quizartinib AC220 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-alpha Inhibitor 7 RET Inhibitor 36 Quizartinib (AC220) targets both wild-type and mutant FLT3 containing activating internal tandem duplications, as well as PDGFRA, RET, and KIT, which may induce apoptosis and inhibit tumor growth (PMID: 19654408, PMID: 23497317).
GTP-14564 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 GTP-14564 is a selective inhibitor of FLT3, c-Fms, c-Kit, and PDGFR-beta, which may result in reduced downstream signaling and subsequent reductions in cell proliferation and tumor growth (PMID: 12815052).
SU14813 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 VEGFR Inhibitor (Pan) 30 SU14813 is a multi-kinase inhibitor with activity against VEGFR1-3, PDGFRA, PDGFRB, KIT, and FLT3, which potentially results in decreased tumor angiogenesis and growth (PMID: 16891463, PMID: 20605934).
Cabozantinib Cometriq Cabometyx|Cabozantinib-s-malate|XL184 AXL Inhibitor 24 FLT3 Inhibitor 48 KIT Inhibitor 48 MET Inhibitor 50 RET Inhibitor 36 ROS1 Inhibitor 14 VEGFR2 Inhibitor 34 Cometriq (Cabometyx, cabozantinib) inhibits several receptor tyrosine kinases, including VEGFR2, FLT3, AXL, MET, RET, ROS1 fusions, and c-KIT (PMID: 27370605, PMID: 21926191). Cometriq (cabozantinib) is FDA approved for medullary thyroid cancer and Cabometyx (cabozantinib) is FDA approved for advanced renal cell carcinoma and in sorafenib previously treated hepatocellular carcinoma (FDA.gov).
TG101209 FLT3 Inhibitor 48 JAK2 Inhibitor - ATP competitive 14 RET Inhibitor 36 TG101209 is an ATP-competitive inhibitor of JAK2, RET, and FLT3 kinases, which may inhibit proliferation and induce apoptosis in cancer cells (PMID: 17541402).
Dovitinib TKI258|CHIR-258 CSF1R Inhibitor 22 FGFR Inhibitor (Pan) 18 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 VEGFR Inhibitor (Pan) 30 Dovitinib (TKI258) targets multiple receptor tyrosine kinases including Flt3, c-Kit, CSF1R, FGFR 1-4, VEGFR 1-3, and PDGFR alpha and beta, potentially resulting in decreased tumor growth (PMID: 15598814, PMID: 25219510, PMID: 23658459, PMID: 16033847).
Lestaurtinib CEP-701 CSF1R Inhibitor 22 FLT3 Inhibitor 48 JAK2 Inhibitor - ATP competitive 14 Trk Receptor Inhibitor (Pan) 23 Lestaurtinib (CEP-701) inhibits JAK2, FLT3 and NTRK1-3, resulting in antiproliferative activity (PMID: 17143529, PMID: 17442779, PMID: 17984313).
Famitinib SHR1020 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 RET Inhibitor 36 VEGFR2 Inhibitor 34 VEGFR3 Inhibitor 5 Famitinib is an analog of Sutent (sunitinib), a receptor tyrosine kinase (RTK) inhibitor, which inhibits receptor tyrosine kinases including c-Kit, VEGFR2/3, PDGFR-beta, RET, and FLT3 to reduce cell proliferation and tumor growth (PMID: 23126373).
Go6976 FLT3 Inhibitor 48 JAK2 Inhibitor 17 PKC alpha Inhibitor 6 PKC beta Inhibitor 6 Go6976 binds and inhibits the calcium-dependent protein kinase C (PKC) isoforms, as well as Flt3, and mutant and wild-type Jak2, which may promote apoptosis and tumor regression (PMID: 8486620, PMID: 16956345).
TP-3654 SGI-9481 FLT3 Inhibitor 48 PIM Inhibitor (Pan) 9 TP-3654 is an inhibitor of PIM1, PIM2, PIM3, and moderately inhibits FLT3, which may result in anti-tumor activity (PMID: 24953177).
Ki23819 FLT3 Inhibitor 48 Ki23819 inhibits both wild-type FLT3 and FLT3 containing activating internal tandem duplications, which may block downstream signaling and induce apoptosis in cancer cells (PMID: 15815726).
AG1295 AG-1295 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 AG1295 inhibits the tyrosine kinase activity of PDGFRA, PDGFRB, KIT, and FLT3, which may inhibit growth and promote apoptosis in cancer cells (PMID: 11468194, PMID: 7954456).
Linifanib ABT-869|AL-39324 CSF1R Inhibitor 22 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 VEGFR Inhibitor (Pan) 30 Linifanib (ABT-869) is a receptor tyrosine kinase inhibitor with specificity against FLT1 (VEGFR1), CSF-1R, KDR (VEGFR2), FLT3, and KIT, which may result in inhibition of cell proliferation and tumor growth, and tumor regression (PMID: 16648571).
TCS 359 FLT3 Inhibitor 48 TCS 359 is a FLT3 inhibitor, which may inhibit the proliferation of cancer cells (PMID: 16580199, PMID: 27099147).
Sorafenib Nexavar BAY 43-9006 CSF1R Inhibitor 22 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 RAF Inhibitor (Pan) 17 RET Inhibitor 36 VEGFR2 Inhibitor 34 Nexavar (sorafenib) is a multikinase inhibitor with activity against several kinases, including RAF kinases, VEGFR2, VEGFR3, PDGFR-beta, KIT, FLT3, RET, and CSF1R, potentially resulting in decreased tumor growth (PMID: 18445656, PMID: 15466206, PMID: 21517818). Nexavar (sorafenib) is approved for metastatic differentiated thyroid carcinoma, hepatocellular carcinoma, and renal cell carcinoma (FDA.gov).
Pacritinib SB1518 FLT3 Inhibitor 48 JAK2 Inhibitor - ATP competitive 14 Pacritinib (SB1518) is an inhibitor of JAK2 and FLT3, with activity against JAK2 V617F and FLT3 ITD, which potentially increases tumor cell apoptosis, induces cell cycle arrest, and decreases tumor growth (PMID: 22829080, PMID: 21691275).
Midostaurin Rydapt PKC412|CGP 41251 CSF1R Inhibitor 22 FLT3 Inhibitor 48 KIT Inhibitor 48 PKC alpha Inhibitor 6 PKC beta Inhibitor 6 PKC Inhibitor (Pan) 9 VEGFR2 Inhibitor 34 Rydapt (midostaurin) is a multi-kinase inhibitor with activity against FLT3, KIT, PDGFRB, KDR (VEGFR2) and PKC, with higher selectivity for conventional PKC isoforms, which induces cell cycle arrest and apoptosis (PMID: 12124173, PMID: 23127174, PMID: 15914319). Rydapt (midostaurin) is FDA approved for FLT3-mutant AML in combination with chemotherapy, and is approved for use in aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia as a single therapy (FDA.gov).
Brigatinib Alunbrig AP26113 ALK Inhibitor 19 EGFR Inhibitor (Pan) 38 FLT3 Inhibitor 48 IGF-1R Inhibitor 17 ROS1 Inhibitor 14 Alunbrig (brigatinib) is a multi-kinase inhibitor with selected activity against ALK, ROS1 fusions, FLT3, IGF1R and mutant EGFR, potentially resulting in decreased tumor growth (PMID: 27780853). Alunbrig (brigatinib) is FDA approved for use in patients with ALK-positive non-small cell lung cancer who have progressed on or are intolerant to crizotinib (FDA.gov).
FN-1501 CDK2 Inhibitor 16 CDK4 Inhibitor 12 CDK6 Inhibitor 3 FLT3 Inhibitor 48 FN-1501 inhibits FLT3, CDK2, CDK4, and CDK6, resulting in decreased downstream signaling and potentially leading to reduced tumor cell proliferation and tumor growth (PMID: 29357250).
XL999 FGFR1 Inhibitor 21 FGFR3 Inhibitor 12 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 RET Inhibitor 36 SRC Inhibitor 26 VEGFR2 Inhibitor 34 XL999 inhibits multiple tyrosine kinases including VEGFR2/KDR, FGFR1/3, PDGFR-beta, FLT3, RET, KIT, and SRC, which can result in anti-tumor activity (J Clin Oncol, 25:18s, 2007 (suppl;abstr 3591), PMID: 19581523).
Sunitinib Sutent SU011248 CSF1R Inhibitor 22 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 RET Inhibitor 36 VEGFR2 Inhibitor 34 Sutent (sunitinib) inhibits KDR (VEGFR2), PDGFR, c-KIT, FLT3, RET, and CSF1R, thereby inhibiting angiogenesis and cell proliferation (NCI Drug Dictionary; PMID: 25085632). Sutent (sunitinib) is approved for neuroendocrine tumors of the pancreas, advanced renal cell carcinoma, and GIST (FDA.gov).
Crenolanib CP-868596 FLT3 Inhibitor 48 PDGFR Inhibitor (Pan) 27 Crenolanib is a type III receptor tyrosine kinase inhibitor of PDGFR-alpha/beta and FLT3, which results in inhibition of downstream signaling and prevents growth in tumor cells (PMID: 22745105).
SAR302503 Fedratinib TG101348 FLT3 Inhibitor 48 JAK2 Inhibitor - ATP competitive 14 RET Inhibitor 36 Fedratinib (SAR302503) binds and inhibits JAK2, FLT3, and RET kinases, which may inhibit cell proliferation and tumor growth (PMID: 17541402).
Gilteritinib Xospata ASP2215 AXL Inhibitor 24 FLT3 Inhibitor 48 Xospata (gilteritinib) is a small molecule inhibitor of FLT3 and AXL that has activity against FLT3-ITD, FLT3 F691L, and FLT3 D835 mutations, potentially resulting in decreased tumor growth (J Clin Oncol 32:5s, 2014 (suppl; abstr 7070), PMID: 25891481). Xospata (gilteritinib) is FDA approved for use in patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation (FDA.gov).
Pexidartinib PLX3397 CSF1R Inhibitor 22 FLT3 Inhibitor 48 KIT Inhibitor 48 Pexidartinib (PLX3397) inhibits multiple receptor tyrosine kinases, including KIT, CSF1R, FLT3, and FLT3/ITD, which may inhibit growth in cancer cells (PMID: 22294205, PMID: 25993548, PMID: 25847190).
SEL24-B489 SEL24 FLT3 Inhibitor 48 PIM Inhibitor (Pan) 9 SEL24-B489 is an inhibitor of PIM kinases 1, 2, 3, and FLT3, which may suppress cell growth and induce apoptosis (Blood 126 (23):706.December 2015).
MRX-2843 FLT3 Inhibitor 48 MRX-2843 is a small molecule inhibitor of both MERTK and FLT3, resulting in apoptosis and anti-tumor effects (PMID: 27158668).
Debio 0617B ABL Inhibitor (pan) 8 CSF1R Inhibitor 22 FLT3 Inhibitor 48 JAK Inhibitor (Pan) 8 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 SRC Inhibitor 26 VEGFR Inhibitor (Pan) 30 Debio 0617B is a multi-kinase inhibitor of SRC, JAK, and ABL, the class III kinases, CSF1R, FLT3, KIT, and PDGFR, and the class V kinases, VEGFR 1/2/3, which may result in inhibition of Stat3 and Stat5 signaling, leading to inhibition of tumor cell growth and metastasis (PMID: 27439479).
Merestinib LY2801653 AXL Inhibitor 24 DDR1 Inhibitor 8 DDR2 inhibitor 7 FLT3 Inhibitor 48 MET Inhibitor 50 RON Inhibitor 10 ROS1 Inhibitor 14 Trk Receptor Inhibitor (Pan) 23 Merestinib (LY2801653) inhibits several receptor tyrosine kinases including MET, MST1R (RON), AXL, MERTK, TYRO3, ROS1 fusions, PDGFRA, FLT3, TEK, DDR1/2, MKNK1/2, and NTRK1/2/3 with greatest activity against NTRK1, and may result in decreased tumor growth (PMID: 23275061, PMID: 24305878, PMID: 29568395).
FLX925 AMG925 CDK4/6 Inhibitor 8 FLT3 Inhibitor 48 FLX925 binds to and inhibits both FMS-related tyrosine kinase 3 (FLT3) and cyclin-dependent kinases 4 and 6 (CDK4/6), resulting in cell cycle arrest and inhibition of cell proliferation (Cancer Res 2015;75(15 Suppl):Abstract nr 787).
Semaxanib SU5416 FLT3 Inhibitor 48 VEGFR1 Inhibitor 4 VEGFR2 Inhibitor 34 Semaxanib (SU5416) is an inhibitor of FLT1 (VEGFR1), KDR (VEGFR2), and FLT3, which inhibits tumor vascularization and growth (PMID: 9892193, PMID: 12351406).
CG'806 BTK inhibitor 20 FLT3 Inhibitor 48 CG'806 is a small molecule multi-kinase inhibitor that inhibits both wild-type and mutant Flt3 and Btk, resulting in growth inhibition in tumor cells (Blood 2017 130:4629).
UNC2025 FLT3 Inhibitor 48 UNC2025 inhibits FLT3 and MER, which may result in decreased growth of MER-dependent and FLT3-dependent tumor cells (PMID: 25068800).
Amuvatinib MP470|HPK56 AXL Inhibitor 24 FLT3 Inhibitor 48 KIT Inhibitor 48 MET Inhibitor 50 PDGFR-alpha Inhibitor 7 RET Inhibitor 36 Amuvatinib (MP470) is a multi-kinase inhibitor, with activity against KIT, MET, AXL, RET, FLT3, and PDGFR-alpha, that also inhibits Rad51 induction, which may enhance the efficacy of chemotherapeutic agents (PMID: 17325667, PMID: 21903282, PMID: 20563581).
ENMD-2076 Aurka Inhibitors 23 FGFR1 Inhibitor 21 FGFR2 Inhibitor 15 FLT3 Inhibitor 48 RET Inhibitor 36 VEGFR2 Inhibitor 34 ENMD-2076 has selective inhibitory activity against Aurora kinase A and FLT3, with reduced potency against RET, KDR (VEGFR2), FGFR1, and FGFR2, preventing angiogenesis and decreasing cell proliferation (PMID: 21177375, PMID: 22921155).
TG02 SB1317 CDK1 Inhibitor 12 CDK2 Inhibitor 16 CDK5 Inhibitor 6 CDK7 Inhibitor 9 CDK9 Inhibitor 12 FLT3 Inhibitor 48 JAK2 Inhibitor 17 TG02 is a pyrimidine-based molecule that inhibits CDK1, CDK2, CDK3, CDK5, CDK7, CDK9, JAK2, and FLT3, which results in growth inhibition in tumor cells (PMID: 21860433).
AGL2043 AGL-2043 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 AGL2043 inhibits the tyrosine kinase activity of PDGFRA, PDGFRB, KIT, and FLT3, which may inhibit growth and promote apoptosis in cancer (PMID: 12670652).
Ponatinib Iclusig AP24534 BCR-ABL Inhibitor 23 DDR1 Inhibitor 8 DDR2 inhibitor 7 FGFR Inhibitor (Pan) 18 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-alpha Inhibitor 7 RET Inhibitor 36 SRC Inhibitor 26 VEGFR Inhibitor (Pan) 30 Iclusig (ponatinib) inhibits the Bcr-Abl fusion, and other tyrosine kinases, such as RET, DDR, VEGFR, FGFR, KIT, and FLT3 (PMID: 23526464, PMID: 25284748, PMID: 19878872). Iclusig (ponatinib) is FDA approved for chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph positive ALL) as well as ABL1 T315I CML and ABL1 T315I Ph positive ALL (FDA.gov).
E6201 FLT3 Inhibitor 48 MEK1 Inhibitor 20 E6201 is a dual inhibitor of MEK1 and FLT3, which may lead to decreased tumor cell growth (Blood Nov 2013, 122 (21) 2683; PMID: 23039341).
G-749 FLT3 Inhibitor 48 G-749 is an inhibitor of both wild-type and mutant forms of FLT3, which may reduce cancer cell proliferation and tumor growth (PMID: 24532805).
Rebastinib DCC-2036 BCR-ABL Inhibitor 23 FLT3 Inhibitor 48 TIE2 Inhibitor 1 VEGFR2 Inhibitor 34 Rebastinib (DCC-2036) inhibits BCR-ABL1 and ABL1 mutations including T315I, and has some activity against TIE-2, FLT3, and VEGFR2, potentially resulting in decreased tumor cell growth (PMID: 21481795).
Tandutinib MLN518|CT53518 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 Tandutinib (CT53518) is a tyrosine kinase inhibitor of FLT3, KIT, and PDGFRbeta, which inhibits cell proliferation and induces apoptosis (PMID: 12166950, PMID: 12124172).
AKN-028 BVT-II|AKN028 FLT3 Inhibitor 48 KIT Inhibitor 48 AKN-028 inhibits wild-type and mutant forms of FLT3 and KIT, potentially resulting in decreased tumor cell proliferation (PMID: 22864397).
BPR1J373 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR Inhibitor (Pan) 27 RET Inhibitor 36 SRC Inhibitor 26 VEGFR Inhibitor (Pan) 30 BPR1J373 is a derivative of 5-phenylthiazol-2-ylamine-pyriminide that inhibits multiple tyrosine kinases including KIT, FLT3, VEGFR1, 2, 3, PDGFR-alpha, PDGFR-beta, RET, and SRC, and may result in anti-tumor activity (PMID: 27512117).
KW-2449 ABL Inhibitor (pan) 8 Aurka Inhibitors 23 FGFR1 Inhibitor 21 FLT3 Inhibitor 48 KW-2449 is a multikinase inhibitor with activity against FLT3, FLT3 D385Y, ABL1, ABL1 T315I, FGFR1, and AURKA, which may inhibit cancer cell proliferation and tumor growth (PMID: 19541823).
Cenisertib AS703569 AURK Inhibitor (Pan) 11 FLT3 Inhibitor 48 Cenisertib (AS703569) is a pan-Aurora kinase inhibitor with additional activity against Flt3 to prevent cell proliferation (PMID: 19609559).
Molecular Profile Protein Effect Treatment Approaches
FLT3 Y599_D600insSTDNEYFYVDFREYEY gain of function - predicted FLT3 Inhibitor
CBL L399P loss of function FLT3 Inhibitor
FLT3 F590_Y591delinsGD gain of function FLT3 Inhibitor
FLT3 F590_F605dup gain of function FLT3 Inhibitor
CBL I383L loss of function FLT3 Inhibitor
FLT3 Y599_D600insEYEYEYEY gain of function - predicted FLT3 Inhibitor
FLT3 D835E gain of function FLT3 Inhibitor
FLT3 V592G gain of function FLT3 Inhibitor
CBL C381R loss of function - predicted FLT3 Inhibitor
FLT3 L611_E612insCSSDNEYFYVDFREYEYDLKWEFPRENL gain of function FLT3 Inhibitor
FLT3 D835N gain of function FLT3 Inhibitor
FLT3 D835G gain of function - predicted FLT3 Inhibitor
CBL E366_K382del loss of function FLT3 Inhibitor
FLT3 S585_F594dup gain of function - predicted FLT3 Inhibitor
FLT3 E598_Y599insDVDFREYE gain of function - predicted FLT3 Inhibitor
CBL K382E loss of function - predicted FLT3 Inhibitor
CBL Y371H loss of function FLT3 Inhibitor
CBL P417A loss of function FLT3 Inhibitor
CBL Y371S loss of function FLT3 Inhibitor
CBL C381A loss of function - predicted FLT3 Inhibitor
FLT3 Y597_K602dup gain of function - predicted FLT3 Inhibitor
CBL H398Y loss of function FLT3 Inhibitor
CBL C384R loss of function FLT3 Inhibitor
CBL Q367P loss of function FLT3 Inhibitor
FLT3 D835H gain of function FLT3 Inhibitor
FLT3 Y599_D600insGLYVDFREYEY gain of function - predicted FLT3 Inhibitor
CBL del loss of function FLT3 Inhibitor
FLT3 L576R gain of function FLT3 Inhibitor
FLT3 F594Y gain of function FLT3 Inhibitor
CBL C384G loss of function FLT3 Inhibitor
CBL W802* loss of function - predicted FLT3 Inhibitor
FLT3 D835V gain of function FLT3 Inhibitor
FLT3 I867S gain of function FLT3 Inhibitor
CBL S376F loss of function FLT3 Inhibitor
FLT3 Y599_D600insPAPQIMSTSTLISENMNIA gain of function - predicted FLT3 Inhibitor
FLT3 F594L gain of function FLT3 Inhibitor
FLT3 act mut gain of function FLT3 Inhibitor
FLT3 I836del gain of function FLT3 Inhibitor
CBL Y371C loss of function FLT3 Inhibitor
FLT3 S840_N841insGS gain of function FLT3 Inhibitor
FLT3 V579A gain of function FLT3 Inhibitor
FLT3 D593_D600dup gain of function - predicted FLT3 Inhibitor
FLT3 exon 14 ins gain of function - predicted FLT3 Inhibitor
CBL R420* loss of function - predicted FLT3 Inhibitor
FLT3 N676K gain of function FLT3 Inhibitor
FLT3 D835A gain of function FLT3 Inhibitor
FLT3 Y842C gain of function FLT3 Inhibitor
FLT3 amp no effect FLT3 Inhibitor
FLT3 E612_F613insGYVDFREYEYDLKWEFRPRENLEF gain of function - predicted FLT3 Inhibitor
CBL R420P loss of function - predicted FLT3 Inhibitor
CBL inact mut loss of function FLT3 Inhibitor
FLT3 V592A gain of function FLT3 Inhibitor
FLT3 D839G gain of function FLT3 Inhibitor
FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE gain of function FLT3 Inhibitor
CBL V391I loss of function FLT3 Inhibitor
FLT3 Y572C gain of function FLT3 Inhibitor
CBL H398Q loss of function - predicted FLT3 Inhibitor
FLT3 Y842H gain of function FLT3 Inhibitor
CBL G375P loss of function - predicted FLT3 Inhibitor
FLT3 W603_E604insDREYEYDLKW gain of function - predicted FLT3 Inhibitor
FLT3 over exp no effect FLT3 Inhibitor
CBL Q367K loss of function FLT3 Inhibitor
FLT3 S451F gain of function FLT3 Inhibitor
CBL C396R loss of function - predicted FLT3 Inhibitor
FLT3 R595_L601dup gain of function FLT3 Inhibitor
CBL Y368C loss of function FLT3 Inhibitor
FLT3 D835del gain of function FLT3 Inhibitor
CBL L399V loss of function - predicted FLT3 Inhibitor
CBL P395A loss of function - predicted FLT3 Inhibitor
CBL R420Q loss of function FLT3 Inhibitor
FLT3 N841I gain of function FLT3 Inhibitor
FLT3 D835Y gain of function FLT3 Inhibitor
FLT3 D835X gain of function - predicted FLT3 Inhibitor
FLT3 F594C gain of function FLT3 Inhibitor
FLT3 F594_D600dup gain of function - predicted FLT3 Inhibitor
CBL Y371D loss of function - predicted FLT3 Inhibitor
CBL Q365_E366insSK loss of function FLT3 Inhibitor
FLT3 A680V gain of function - predicted FLT3 Inhibitor
FLT3 R834Q gain of function FLT3 Inhibitor